CANAKINUMAB (ILARIS®)

DRUG2 trials

Sponsors

PD Dr. med. Stephan Michels, Massachusetts General Hospital

Conditions

ASCVDASCVD ManagementProliferative Diabetic RetinopathyVascular Inflammation

Phase 1

A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP)

TerminatedNCT01589029

PD Dr. med. Stephan MichelsProliferative Diabetic Retinopathy

Start: 2012-04-30End: 2014-11-30Updated: 2015-11-24

Phase 2

Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

RecruitingNCT06691217

Massachusetts General HospitalASCVD, ASCVD Management, Vascular Inflammation

Start: 2026-03-24End: 2030-04-01Target: 120Updated: 2026-06-18